Home > Cardiology > HFA 2022 > Delayed initiation of novel GDMTs may wreak havoc on HF patients

Delayed initiation of novel GDMTs may wreak havoc on HF patients

Presented By
Dr Gianluigi Savarese, Karolinska University Hospital, Sweden
Conference
HFA 2022
Trial
EVOLUTION-HF
The initiation of treatment with novel guideline-directed medical therapies (GDMTs) for heart failure (HF), namely SGLT2  and ARN inhibitors, is delayed compared to that of pre-existing GDMTs in patients 1 year after HF hospitalisation. Additionally, these novel GDMTs tend to only be administered very late after the initial diagnosis of HF. These findings stress the need for earlier administration of the novel GDMTs [1]. Guidelines recommend that GDMTs should be initiated swiftly after the initial diagnosis of HF [2]. The multinational, observational EVOLUTION-HF study aimed to objectify patterns in patients with newly initiated GDMT treatment after HF hospitalisation. In total, 194,181 patients from Japan, Sweden, and the USA, who had initiated treatment with at least one GDMT within 12 months of discharge after HF hospitalisation were included. Dr Gianluigi Savarese (Karolinska University Hospital, Sweden) presented the results of the study. The i...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on